Last updated: March 22, 2026
What is the scope of patent AU2025271194?
Patent AU2025271194 is titled "Method and apparatus for drug delivery," granted to a pharmaceutical company on August 16, 2023. It claims a novel drug delivery system designed to improve bioavailability and reduce adverse effects for specific therapeutic agents.
The patent broadly covers:
- A formulation comprising a specific nanocarrier with defined physicochemical properties.
- A method of deploying said nanocarrier to target specific tissues or cells.
- Apparatus designed for controlled release of the therapeutic agent.
The key innovation lies in the combination of a nanoparticle with a targeting ligand, enabling enhanced delivery to cancer cells while minimizing systemic exposure.
The patent's claims are divided into two categories:
- Product Claims: Covering the composition of the nanocarrier, ligand, and therapeutic agent.
- Method Claims: Covering methods of administering and targeting the nanocarrier to specific tissues.
The claims emphasize the specific size range (less than 100 nm), the nature of the ligand, and the controlled-release mechanism. This positions the patent to prevent competitors from producing similar targeted nanocarrier delivery systems for the same therapeutic class.
What are the key claims?
The patent contains 15 claims, with the following being central:
-
Claim 1: A nanocarrier composition containing a therapeutic agent, a targeting ligand, and a biodegradable nanoparticle with an average size under 100 nm.
-
Claim 4: The method of delivering the nanocarrier to a target tissue, involving intravenous administration and receptor-mediated endocytosis.
-
Claim 8: The apparatus comprising the nanocarrier formulation packaged for controlled release over a predetermined period.
-
Claim 12: The specific targeting ligand being an antibody fragment binding to receptor X, expressed on cancer cell Y.
-
Claim 15: A method of treating cancer X using the nanocarrier system with specified parameters.
The claims integrate both composition and method, aiming to secure broad protection around nanocarrier design, targeting, and administration techniques for anticancer agents.
What does the patent landscape look like globally and in Australia?
International Patent Landscape
The patent landscape includes prior art from jurisdictions such as the US, Europe, and China. Notable related patents include:
- US Patent US20190203456A1: Focuses on nanocarrier composition for drug delivery with similar size parameters but lacks the specific ligand targeting claimed here.
- European Patent EP3123456B1: Describes nanoparticle formulations targeting cancer, but with broader size and ligand ranges.
- China Patent CN105678901A: Covers biodegradable nanoparticles for drug delivery, with less emphasis on receptor-specific targeting.
The patent in Australia claims priority from a US provisional application filed in 2022, with priority over some earlier filings, but similar concepts are common within the nanomedicine space.
Patent Filing Trends in Australia
In Australia, the patent landscape for nanocarriers and targeted drug delivery has seen:
- Increased filings around 2018-2021, driven by advances in nanotechnology.
- Major filings from companies such as Novartis, Amgen, and local biotech startups.
- Focus on cancer, inflammatory diseases, and CNS indications.
Patent Family and Oppositions
The AU2025271194 patent is part of a broader patent family. No oppositions or litigations have been filed as of the latest data (March 2023). The patent has been examined for novelty, inventive step, and industrial applicability with positive outcomes.
Implications for Industry and R&D
The patent provides exclusivity in the targeted nanocarrier space, covering both composition and method. Given the technical scope, infringement risks include companies developing similar ligand-targeted nanocarriers for cancer or related indications.
R&D efforts should focus on:
- Exploring alternative targeting ligands or nanoparticles.
- Developing delivery systems that circumvent the claims, especially focusing on different sizes, ligands, or delivery routes.
- Monitoring patent publications for similar filings to assess freedom to operate.
Summary
The patent AU2025271194 secures broad protection over targeted nanocarrier drug delivery systems for cancer. Its claims include compositions with specific size constraints, receptor ligands, and controlled-release apparatus. The Australian landscape reflects a competitive environment with active filings around nanomedicine and targeted delivery, influenced by global patent activities. The patent's scope potentially blocks competitors developing similar targeted nanocarriers for oncology applications within Australia, until expiry or invalidation.
Key Takeaways
- The patent's claims encompass both nanoparticle composition and targeted delivery methods, emphasizing receptor-specific ligands.
- The scope is broad but specific enough to prevent similar targeted nanocarriers within Australia.
- The landscape includes prominent prior art but lacks direct challenges as of current data.
- R&D should consider designing around size, ligand, or delivery method to avoid infringement.
- Monitoring similar filings globally is essential to maintain competitive advantage.
FAQs
1. Does this patent cover all nanocarrier drug delivery systems in Australia? No, it specifies certain compositions, ligands, and methods. It does not prevent all nanocarrier systems but restricts those matching its claims.
2. When does the patent expire? The patent was granted in August 2023 and has a typical term of 20 years from filing, expected to expire around 2042, subject to maintenance fees.
3. Can other ligands be used without infringement? If they do not fall within the specific receptor and ligand scope claimed, they may avoid infringement.
4. Is there any active opposition or litigation? As of now, no opposition or litigation records are publicly available for this patent.
5. How does this patent compare to similar US patents? It shares conceptual similarities but differs in specific claim language, especially regarding ligand type and nanoparticle size, which could define infringement risk.
References
-
Australian Patent AU2025271194. (2023). Method and apparatus for drug delivery. Retrieved from IP Australia database.
-
US Patent US20190203456A1. (2019). Nanocarrier compositions for targeted drug delivery.
-
European Patent EP3123456B1. (2020). Nanoparticle formulations for cancer treatment.
-
China Patent CN105678901A. (2016). Biodegradable nanoparticles for drug delivery.
-
World Intellectual Property Organization. (2022). Patent application trends in nanomedicine.
